CoChat
Sign Up
Cited by 244

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Frontline therapy of multiple myeloma

Moreau, Philippe, Attal, Michel, Facon, Thierry·2015·Blood
DOI 10.1182/blood-2014-09-568915
Open this paper in CoChat — free account

Abstract

In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents, thalidomide, bortezomib, and lenalidomide, as part of frontline treatment in both transplant and nontransplant candidates. These drugs have markedly improved the rate of complete remission, and time to progression, progression-free survival, and overall survival have significantly increased. This article focuses on more recent frontline therapeutic approaches both in older patients, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in younger patients eligible for early ASCT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2014-09-568915

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 9 references

Research works printed but not linked: 80

  1. Howlade, 2012, SeerSEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations)
  2. Becker, 2011, Epidemiology of multiple myeloma., Recent Results Cancer Res, 183, 25, 10.1007/978-3-540-85772-3_2 · DOI
  3. Landgren, 2013, Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies., Hematology Am Soc Hematol Educ Program, 2013, 478, 10.1182/asheducation-2013.1.478 · DOI
  4. Kyle, 2010, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management., Leukemia, 24, 1121, 10.1038/leu.2010.60 · DOI
  5. Moreau, 2013, Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol, 24, vi133, 10.1093/annonc/mdt297 · DOI
  6. Cavo, 2011, International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation., Blood, 117, 6063, 10.1182/blood-2011-02-297325 · DOI
  7. Moreau, 2011, Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies., J Clin Oncol, 29, 1898, 10.1200/JCO.2010.32.5878 · DOI
  8. Palumbo, 2014, International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation., J Clin Oncol, 32, 587, 10.1200/JCO.2013.48.7934 · DOI
  9. Attal, 1996, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome., N Engl J Med, 335, 91, 10.1056/NEJM199607113350204 · DOI · Paper page
  10. Harousseau, 2010, Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial., J Clin Oncol, 28, 4621, 10.1200/JCO.2009.27.9158 · DOI
  11. Stewart, 2009, How I treat multiple myeloma in younger patients., Blood, 114, 5436, 10.1182/blood-2009-07-204651 · DOI · Paper page
  12. Cavo, 2010, Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study., Lancet, 376, 2075, 10.1016/S0140-6736(10)61424-9 · DOI
  13. Moreau, 2011, Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma., Blood, 118, 5752, 10.1182/blood-2011-05-355081 · DOI
  14. Rosiñol, 2012, Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study., Blood, 120, 1589, 10.1182/blood-2012-02-408922 · DOI
  15. Kumar, 2012, Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma., Blood, 119, 4375, 10.1182/blood-2011-11-395749 · DOI · Paper page
  16. Sonneveld, 2013, Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials., J Clin Oncol, 31, 3279, 10.1200/JCO.2012.48.4626 · DOI
  17. Moreau, 2002, Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial., Blood, 99, 731, 10.1182/blood.V99.3.731 · DOI
  18. Bayraktar, 2013, Fifty years of melphalan use in hematopoietic stem cell transplantation., Biol Blood Marrow Transplant, 19, 344, 10.1016/j.bbmt.2012.08.011 · DOI
  19. Sonneveld, 2012, Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial., J Clin Oncol, 30, 2946, 10.1200/JCO.2011.39.6820 · DOI · Paper page
  20. Cavo, 2007, Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study., J Clin Oncol, 25, 2434, 10.1200/JCO.2006.10.2509 · DOI · Paper page
  21. Gertz, 2014, How we manage autologous stem cell transplantation for patients with multiple myeloma., Blood, 124, 882, 10.1182/blood-2014-03-544759 · DOI
  22. Cavo, 2012, Impact of bortezomib incorporated into autotransplantation on outcomes of myeloma patients with high-risk cytogenetics: an integrated analysis of 1894 patients enrolled in four European phase 3 studies [abstract]., Blood, 120, 10.1182/blood.V120.21.749.749 · DOI
  23. Ladetto, 2010, Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma., J Clin Oncol, 28, 2077, 10.1200/JCO.2009.23.7172 · DOI
  24. Cavo, 2012, Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma., Blood, 120, 9, 10.1182/blood-2012-02-408898 · DOI
  25. Mellqvist, 2013, Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial., Blood, 121, 4647, 10.1182/blood-2012-11-464503 · DOI
  26. Leleu, 2013, Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma., Leukemia, 27, 2242, 10.1038/leu.2013.101 · DOI
  27. Roussel, 2014, Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study of the Intergroupe Francophone du Myélome., J Clin Oncol, 32, 2712, 10.1200/JCO.2013.54.8164 · DOI
  28. McCarthy, 2013, Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients., Hematology Am Soc Hematol Educ Program, 2013, 496, 10.1182/asheducation.V2013.1.496.3847117 · DOI
  29. Barlogie, 2008, Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities., Blood, 112, 3115, 10.1182/blood-2008-03-145235 · DOI
  30. Attal, 2006, Maintenance therapy with thalidomide improves survival in multiple myeloma patients., Blood, 108, 3289, 10.1182/blood-2006-05-022962 · DOI
  31. Spencer, 2009, Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure., J Clin Oncol, 27, 1788, 10.1200/JCO.2008.18.8573 · DOI
  32. Lokhorst, 2010, A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma., Blood, 115, 1113, 10.1182/blood-2009-05-222539 · DOI
  33. Morgan, 2012, The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis., Blood, 119, 7, 10.1182/blood-2011-06-357038 · DOI
  34. Stewart, 2013, A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial., Blood, 121, 1517, 10.1182/blood-2012-09-451872 · DOI
  35. Rosiñnol, 2012, Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib/thalidomide vs thalidomide vs alfa2b-interferon: final results of a phase 3 PETHEMA/GEM randomized trial. ASH annual meeting abstracts [abstract]., Blood, 120, 10.1182/blood.V120.21.334.334 · DOI
  36. Usmani, 2013, Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?, Leukemia, 27, 226, 10.1038/leu.2012.160 · DOI
  37. Rajkumar, 2010, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial., Lancet Oncol, 11, 29, 10.1016/S1470-2045(09)70284-0 · DOI · Paper page
  38. Richardson, 2010, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma., Blood, 116, 679, 10.1182/blood-2010-02-268862 · DOI · Paper page
  39. Jakubowiak, 2012, A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma., Blood, 120, 1801, 10.1182/blood-2012-04-422683 · DOI
  40. Korde, 2013, Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients [abstract]., Blood, 122, 10.1182/blood.V122.21.538.538 · DOI
  41. Kumar, 2012, Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma., Cancer, 118, 1585, 10.1002/cncr.26422 · DOI
  42. Dunavin, 2013, Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma., Leuk Lymphoma, 54, 1658, 10.3109/10428194.2012.751528 · DOI
  43. Siegel, 2010, Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in the ECOG E4A03 randomized clinical trial [abstract]., Blood, 116, 10.1182/blood.V116.21.38.38 · DOI
  44. Palumbo, 2013, A phase III study of ASCT vs cyclophosphamide-lenalidomide-dexamethasone and lenalidomide-prednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients [abstract]., Blood, 122
  45. Moreau, 2011, Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial., Blood, 117, 3041, 10.1182/blood-2010-08-300863 · DOI
  46. Pandya, 2014, Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma., Clin Transplant, 28, 1084, 10.1111/ctr.12421 · DOI
  47. Passweg, 2013, Hematopoietic SCT in Europe: data and trends in 2011., Bone Marrow Transplant, 48, 1161, 10.1038/bmt.2013.51 · DOI
  48. Facon, 2007, Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial., Lancet, 370, 1209, 10.1016/S0140-6736(07)61537-2 · DOI
  49. Fayers, 2011, Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials., Blood, 118, 1239, 10.1182/blood-2011-03-341669 · DOI
  50. Palumbo, 2011, Multiple myeloma., N Engl J Med, 364, 1046, 10.1056/NEJMra1011442 · DOI
  51. Hulin, 2009, Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial., J Clin Oncol, 27, 3664, 10.1200/JCO.2008.21.0948 · DOI
  52. Wijermans, 2010, Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study., J Clin Oncol, 28, 3160, 10.1200/JCO.2009.26.1610 · DOI
  53. Palumbo, 2006, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial., Lancet, 367, 825, 10.1016/S0140-6736(06)68338-4 · DOI
  54. Palumbo, 2008, Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial., Blood, 112, 3107, 10.1182/blood-2008-04-149427 · DOI
  55. Waage, 2010, Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma., Blood, 116, 1405, 10.1182/blood-2009-08-237974 · DOI
  56. Beksac, 2011, Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group., Eur J Haematol, 86, 16, 10.1111/j.1600-0609.2010.01524.x · DOI
  57. Morgan, 2011, Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation., Blood, 118, 1231, 10.1182/blood-2011-02-338665 · DOI
  58. San Miguel, 2008, Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma., N Engl J Med, 359, 906, 10.1056/NEJMoa0801479 · DOI · Paper page
  59. San Miguel, 2013, Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma., J Clin Oncol, 31, 448, 10.1200/JCO.2012.41.6180 · DOI
  60. Mateos, 2010, Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial., Lancet Oncol, 11, 934, 10.1016/S1470-2045(10)70187-X · DOI · Paper page
  61. Palumbo, 2014, Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival., J Clin Oncol, 32, 634, 10.1200/JCO.2013.52.0023 · DOI
  62. Mateos, 2012, Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial., Blood, 120, 2581, 10.1182/blood-2012-05-427815 · DOI
  63. Niesvizky, 2013, Efficacy and safety of three bortezomib-based induction and maintenance regimens in previously untreated, transplant-ineligible multiple myeloma (MM) patients (Pts): final results from the randomized, phase 3b, US community-based UPFRONT Study (NCT00507416) [abstract]., Blood, 122, 10.1182/blood.V122.21.1966.1966 · DOI
  64. Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma., N Engl J Med, 366, 1759, 10.1056/NEJMoa1112704 · DOI
  65. Pönisch, 2006, Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)., J Cancer Res Clin Oncol, 132, 205, 10.1007/s00432-005-0074-4 · DOI
  66. Mateos, 2013, Phase 2 study of bendamustine, bortezomib (velcade) and prednisone (BVP) for newly diagnosed multiple myeloma (MM) [abstract]., Blood, 122, 10.1182/blood.V122.21.2155.2155 · DOI
  67. Berdeja, 2013, Bendamustine, bortezomib and dexamethasone (BBD) as first-line treatment of patients (Pts) with multiple myeloma who are not candidates for high dose chemotherapy [abstract]., Blood, 122, 10.1182/blood.V122.21.3193.3193 · DOI
  68. Ludwig, 2014, European perspective on multiple myeloma treatment strategies in 2014., Oncologist, 19, 829, 10.1634/theoncologist.2014-0042 · DOI
  69. Larocca, 2013, A simple score, based on geriatric assessment, improves prediction of survival, and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients [abstract]., Blood, 122, 10.1182/blood.V122.21.687.687 · DOI
  70. Avet-Loiseau, 2013, Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du Myélome experience., J Clin Oncol, 31, 2806, 10.1200/JCO.2012.46.2598 · DOI
  71. European Commission, 2009, 2009 Ageing report: economic and budgetary projections for the EU-27 Member States (2008-2060)
  72. Larocca, 2013, Reduced dose-intensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosfamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of age [abstract]., Blood, 122, 10.1182/blood.V122.21.539.539 · DOI
  73. Bringhen, 2013, Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials., Haematologica, 98, 980, 10.3324/haematol.2012.075051 · DOI
  74. Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation., J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 · DOI · Paper page
  75. Katz, 1963, Studies of illness in the aged. The Index of ADL: a standardized measure of biological and psychosocial function., JAMA, 185, 914, 10.1001/jama.1963.03060120024016 · DOI · Paper page
  76. Lawton, 1988, Scales to measure competence in everyday activities., Psychopharmacol Bull, 24, 609
  77. Soubeyran, 2008, Validation of a screening test for elderly patients in oncology [abstract]., J Clin Oncol, 26
  78. Mateos, 2013, Comparison of sequential vs alternating administration of bortezomib, melphalan and prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly patients with newly diagnosed multiple myeloma (MM) patients: GEM2010MAS65 Trial [abstract]., Blood, 122, 10.1182/blood.V122.21.403.403 · DOI
  79. Facon, 2006, Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy., Blood, 107, 1292, 10.1182/blood-2005-04-1588 · DOI
  80. Hernández, 2004, Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma., Br J Haematol, 127, 159, 10.1111/j.1365-2141.2004.05186.x · DOI

Cited by

Sorted by citations

See all 244

Metadata

Authors
Moreau, P., Attal, M., & Facon, T.
Venue
Blood
Publisher
American Society of Hematology
Published
2015-05-14
Volume
125
Issue
20
Pages
3076-3084
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2014-09-568915
Cited by
244
References
9
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review